Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) EBT: 2018-2025

Historic EBT for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Sep 2025 value amounting to -$13.4 million.

  • Arcturus Therapeutics Holdings' EBT fell 88.88% to -$13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.7 million, marking a year-over-year decrease of 6.94%. This contributed to the annual value of -$80.9 million for FY2024, which is 190.23% down from last year.
  • According to the latest figures from Q3 2025, Arcturus Therapeutics Holdings' EBT is -$13.4 million, which was down 46.56% from -$9.2 million recorded in Q2 2025.
  • Arcturus Therapeutics Holdings' 5-year EBT high stood at $118.6 million for Q4 2022, and its period low was -$57.7 million during Q1 2021.
  • For the 3-year period, Arcturus Therapeutics Holdings' EBT averaged around -$13.2 million, with its median value being -$14.1 million (2025).
  • In the last 5 years, Arcturus Therapeutics Holdings' EBT slumped by 509.45% in 2021 and then soared by 415.16% in 2022.
  • Over the past 5 years, Arcturus Therapeutics Holdings' EBT (Quarterly) stood at -$37.6 million in 2021, then skyrocketed by 415.16% to $118.6 million in 2022, then tumbled by 109.65% to -$11.4 million in 2023, then crashed by 162.20% to -$30.0 million in 2024, then crashed by 88.88% to -$13.4 million in 2025.
  • Its EBT was -$13.4 million in Q3 2025, compared to -$9.2 million in Q2 2025 and -$14.1 million in Q1 2025.